OSE Immunotherapeutics to Present New Clinical and Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Regulatory News:

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that three abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 36^th Annual Meeting in Washington D.C. (and virtually) held on November 10 – 14, 2021. The three posters will include new clinical and translational data on Tedopi (neoepitope-based cancer vaccine) in non-small cell lung cancer and the latest data on preclinical programs BiCKI-IL-7 (bifunctional therapy targeting PD-1 and IL-7) and CLEC-1 (new “Don’t Eat Me” myeloid checkpoint target).

POSTER PRESENTATION DETAILS

- Title: “Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial” (poster #366)
Category: Clinical trials completed
Presentation Time: November 12 - 14, 2021
Location: Poster Hall

- Title: “Long-term anti-tumor preclinical efficacy of an optimized anti-PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity” (poster #794)
Category: Immunoconjugates and chimeric molecules
Presentation Time: November 12 - 14, 2021
Location: Poster Hall

- Title: “Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology” (poster #230)
Category: Checkpoint blockade therapy
Presentation Time: November 12 - 14, 2021
Location: Poster Hall

ABOUT OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile:
Vaccine platform
- Tedopi (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients after secondary resistance to checkpoint inhibitors.
In Phase 2 in pancreatic cancer (TEDOPaM), sponsor GERCOR.
In Phase 2 in ovary cancer, in combination with pembrolizumab (TEDOVA), sponsor ARCAGY-GINECO.
In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.